<DOC>
	<DOCNO>NCT01941940</DOCNO>
	<brief_summary>This open-label , single arm , Phase 3b study evaluate efficacy tocilizumab ( RoActemra ) , administer monotherapy combination methotrexate and/or DMARDs , participant moderate severe active RA .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Tocilizumab Administered Monotherapy Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs ( DMARDs ) Rheumatoid Arthritis ( RA ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis active RA accord revise ( 1987 ) ACR criterion EULAR/ACR ( 2010 ) criterion Moderate severe RA ( CDAI least [ &gt; /= ] 10 DAS28 &gt; /=3.2 ) screen Tumor necrosis factor inhibitorsinadequate responder ( TNFIR ) , methotrexateinadequate responder ( MTXIR ) , and/or DMARDsinadequate responder ( DMARDsIR ) Oral corticosteroid ( less equal [ &lt; /= ] 10 mg per day prednisone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ; maximum recommend dose ) permit stable dose regimen &gt; /=4 week prior baseline Permitted nonbiologic DMARDs allow stable dose &gt; /=4 week prior baseline Receiving treatment outpatient basis , include tocilizumab Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception least 3 month follow last dose tocilizumab Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 12 month follow baseline Rheumatic autoimmune disease RA ; secondary Sj√∂gren 's syndrome RA permit Functional Class IV define ACR Classification Functional Status RA Diagnosis juvenile idiopathic arthritis juvenile RA and/or RA age 16 Prior history current inflammatory joint disease RA Exposure tocilizumab ( either intravenous [ IV ] SC ) time prior baseline Treatment investigational agent within 4 week ( 5 halflives investigational drug , whichever long ) screen Previous treatment celldepleting therapy Intraarticular parenteral corticosteroid within 4 week prior baseline History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Evidence serious uncontrolled concomitant cardiovascular , nervous system , pulmonary , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) , gastrointestinal disease Known active current history recurrent bacterial , viral , fungal , mycobacterial , infection Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week screen Active tuberculosis ( TB ) require treatment within previous 3 year Positive hepatitis B surface antigen hepatitis C antibody Primary secondary immunodeficiency ( history currently active ) Evidence active malignant disease , malignancy diagnose within previous 10 year ( except basal squamous cell carcinoma skin carcinoma situ cervix uterus excise cure ) , breast cancer diagnose within previous 20 year Pregnant breast feed woman Neuropathies condition might interfere pain evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>